Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

simtuzumab

- PMLiVE

FDA approves Gilead’s ‘universal’ hep C combination Epclusa

Adds a third Sovaldi-based treatment to the firm’s portfolio

- PMLiVE

Aduro pancreatic cancer vaccine trial disappoints

Immunotherapy combination fails to improve overall survival over existing treatments

- PMLiVE

Paywatch and the market access waters

Understanding and responding to payers’ needs has become priority number one for pharma

german flag

Germany planning to table pricing reforms ‘by the summer’

Proposed changes include replacing 12-month full price policy with €250m threshold

Gilead Sciences

Gilead must pay just $200m for hep C patents, says jury

Merck & Co awarded a 4% royalty rate on sales of Sovaldi and Harvoni

- PMLiVE

Merck & Co wins hepatitis C patent dispute with Gilead

US jury upholds claim that Sovaldi and Harvoni infringe two sofosbuvir patents

Celgene building

Wales backs NHS use of Abraxane despite NICE rejection

Overrules UK decision and will maintain access to Celgene’s pancreatic cancer drug

Gilead Sciences

Gilead wins US approval for second TAF-based HIV drug

FDA gives Odefsey the green light

- PMLiVE

Incyte abandons solid tumour programme for Jakafi

Drug discontinued after failure to show efficacy in trials

Gilead Sciences

Priority FDA review for new Gilead HCV combination therapy

Sovaldi/velpatasvir combination could be approved in the US by summer 2016

Gilead Sciences

Gilead steps into breach left by AbbVie as Galapagos’ partner

Deal worth $2bn to help rheumatoid arthritis drug filgotinib make it through to the market

Gilead Sciences

Gilead’s HIV drug Genvoya cleared in EU

First TAF-based regimen to be approved in the US and EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links